Introduction: The aim of this study was to report a case of cervical cancer stage IB2 treated with neoadjuvant chemotherapy, followed by simultaneous robotic-assisted radical trachelectomy and reversal of tubal sterilization.
Case Description: This case occurred in a university hospital involving a 31-y-old woman with stage IB2 cervical cancer treated using neoadjuvant chemotherapy, robotic surgery, and tubal anastomosis to determine cancer disease status and achieve restoration of tubal patency.
Discussion: A successful radical trachelectomy with patent tubes was done bilaterally. Cancer and fertility procedures can be simultaneously implemented and achieved.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558908 | PMC |
| http://dx.doi.org/10.4293/108680812X13517013316555 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objectives: To evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high-risk upper tract urothelial carcinoma (UTUC) using a large, well-curated multi-institutional database.
Patients And Methods: This study was a multi-institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high-volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC.
Role of mast cell in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
BMC Cancer
January 2025
Department of Surgery, Tokushima University, 3-18-15 Kuramoto-Cho, Tokushima, 770-8503, Japan.
The pro-tumor effects of mast cell (MC) in the tumor microenvironment (TME) are becoming increasingly clear. Recently, MC were shown to contribute to tumor malignancy by supporting the migration of tumor-associated macrophages (TAMs), suggesting a relationship with tumor immunity. In the current study, we aimed to examine the correlation between MC infiltration and neoadjuvant chemoradiotherapy (nCRT) response for locally advanced rectal cancer (LARC).
View Article and Find Full Text PDFLow-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Support Care Cancer
January 2025
Department of Acute Medicine, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK.
Purpose: Management of patients with low-risk febrile neutropenia in an outpatient setting guided by the MASCC score is proven to be safe and effective. Most patients on ambulatory low-risk febrile neutropenia pathways are undergoing treatment for breast cancer. Recent data has shown benefit of the addition of immune checkpoint inhibitor therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple-negative breast cancer.
View Article and Find Full Text PDFTreatment strategy involving docetaxel plus cisplatin and 5-fluorouracil followed by conversion surgery for locally advanced unresectable/borderline resectable esophageal squamous cell carcinoma.
Dis Esophagus
January 2025
Department of Esophageal Surgery, National Cancer Center, Tokyo, Japan.
Definitive chemoradiotherapy (dCRT) is the standard treatment for unresectable (T4) esophageal squamous cell carcinoma (ESCC), but the prognosis is poor. Borderline resectable (T3br) ESCC has been discussed, but its clinical features and appropriate treatment are unclear. The effects of docetaxel plus cisplatin and 5-fluorouracil (DCF) therapy and subsequent surgery for potentially unresectable ESCC remain controversial.
View Article and Find Full Text PDFTumour volume analysis applied to imaging and histological examinations in breast cancer.
Eur J Surg Oncol
January 2025
Imperial College Healthcare Trust, Fulham Palace Road, London, W6 8RF, England, UK. Electronic address:
Purpose: Response Evaluation Criteria in Solid Tumours (RECIST) determines partial response (PR) and progressive disease (PD) as a 30 % reduction and 20 % increase in the longest diameter (LD), respectively. Tumour volume analysis (TVA) utilises three diameters to calculate response parameters.
Patients And Methods: We conducted a pilot investigation of patients who underwent neoadjuvant breast cancer treatment and evaluation using RECIST with LD measurements and TVA with three diametric measurements, using the parameters PR (>30 % tumour regression), PD (>20 % tumour growth), and intermediate stable disease (SD).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!